The Food and Drug Administration’s approval of Biogen and Eisai’s anti-amyloid antibody aducanumab on June 7 left many questions unanswered, including how to use the drug in clinical practice. Since ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback